Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026 Shuhua Xia, PhDCEO at Nanjing Diligene BiotechnologiesSpeaker
Profile
Dr. Shuhua Xia has over 20 years of experience in the biotech industry, with expertise in the development of antibody-based therapeutics.Prior to joining DiligeneBio, Dr. Xia spent more than 15 years at Pfizer’s R&D division, where he worked across multiple biotherapeutic areas—including antibodies and antibody-drug conjugates (ADCs). Notably, he contributed to the development of the ADC drug inotuzumab ozogamicin, which was successfully launched. Dr. Xia holds a Ph.D. in Genetics from Peking Union Medical College and a MS degree in Biostatistics from Texas A&M University. He finished his postdoc. training at Harvard Medical School.
Agenda Sessions
A Novel bsADC for Glioblastoma (GBM)
, 16:45View Session